#1 Clinical Trials Search in Europe

Pelacarsen

Pelacarsen, also known as TQJ230, is an innovative drug being studied in clinical trials for its potential to treat cardiovascular disease, particularly in patients with elevated levels of lipoprotein(a) [Lp(a)]. This article explores the ongoing research into Pelacarsen’s efficacy, safety, and potential benefits for patients with various cardiovascular conditions.

Table of Contents

What is Pelacarsen?

Pelacarsen, also known as TQJ230, AKCEA-APO(a)-LRx, or ISIS 681257, is a new medication being developed to treat cardiovascular diseases[1]. It belongs to a class of drugs called antisense oligonucleotides (ASOs), which are designed to target specific genetic material in the body[2].

How Pelacarsen Works

Pelacarsen works by reducing the production of a substance in the body called lipoprotein(a), or Lp(a) for short. Lp(a) is a type of fat-protein particle in the blood that can contribute to the development of heart disease. The medication targets the genetic material (mRNA) responsible for producing Lp(a) in the liver, effectively lowering its levels in the blood[2].

Conditions Treated by Pelacarsen

Pelacarsen is being studied for the treatment of several cardiovascular conditions, including:

  • Hyperlipoproteinemia(a): A condition characterized by high levels of Lp(a) in the blood, which increases the risk of heart disease[3]
  • Cardiovascular Disease: Including conditions such as heart attacks, strokes, and peripheral artery disease[3]
  • Calcific Aortic Valve Stenosis: A condition where the heart’s aortic valve narrows due to calcium buildup, making it harder for the heart to pump blood[4]

Current Clinical Trials

Pelacarsen is currently being studied in several clinical trials to evaluate its effectiveness and safety. Some of these trials include:

  • A study to assess the long-term safety and effectiveness of Pelacarsen in patients with cardiovascular disease who have completed previous trials[3]
  • A trial investigating how Pelacarsen affects the progression of calcific aortic valve stenosis[4]
  • A study examining the effects of Pelacarsen on patients who have had a heart attack and have high Lp(a) levels[2]
  • A trial assessing whether Pelacarsen can reduce the need for lipoprotein apheresis (a blood-cleaning procedure) in patients with high Lp(a) levels[5]

How Pelacarsen is Administered

Pelacarsen is typically administered as a subcutaneous injection (an injection under the skin). In most clinical trials, it is given at a dose of 80 mg once a month[3][5]. However, the exact dosing may vary depending on the specific study or patient needs.

Potential Benefits of Pelacarsen

The potential benefits of Pelacarsen include:

  • Significant reduction in Lp(a) levels, which may lower the risk of cardiovascular events[2]
  • Possible slowing of the progression of calcific aortic valve stenosis[4]
  • Potential reduction in the need for lipoprotein apheresis procedures for patients with high Lp(a) levels[5]
  • Improved cardiovascular health and potentially reduced risk of heart attacks and strokes[2]

Safety and Side Effects

As Pelacarsen is still in clinical trials, its full safety profile is not yet established. The ongoing studies are carefully monitoring for any adverse events or side effects. Common measures being tracked include:

  • Changes in laboratory test results[1]
  • Occurrence of adverse events and serious adverse events[1]
  • Effects on liver function, especially in patients with mild liver impairment[6]

It’s important to note that as with any medication, individual responses may vary, and patients should always consult with their healthcare provider about potential risks and benefits.

Aspect Details
Drug Name Pelacarsen (TQJ230)
Drug Type Antisense oligonucleotide (ASO)
Target Apolipoprotein(a) mRNA
Primary Indication Reduction of lipoprotein(a) [Lp(a)] levels
Administration Subcutaneous injection, typically 80 mg monthly
Key Study Populations Patients with ASCVD, hyperlipoproteinemia(a), calcific aortic valve stenosis
Primary Outcomes Lp(a) reduction, lipoprotein apheresis reduction, slowing of aortic valve stenosis progression
Safety Monitoring Adverse events, laboratory evaluations, vital signs
Potential Benefits Cardiovascular risk reduction, improved quality of life, reduced need for apheresis

FAQ

  • What is Pelacarsen and how does it work? Pelacarsen is an antisense oligonucleotide (ASO) drug that targets the messenger RNA (mRNA) of apolipoprotein(a). It works by reducing the production of apolipoprotein(a) in the liver, which in turn lowers the levels of lipoprotein(a) [Lp(a)] in the blood. Lp(a) is a known risk factor for cardiovascular disease.
  • What conditions is Pelacarsen being studied for? Pelacarsen is being investigated for various cardiovascular conditions, including atherosclerotic cardiovascular disease (ASCVD), hyperlipoproteinemia(a), and calcific aortic valve stenosis. It's particularly focused on patients with elevated Lp(a) levels who are at higher risk for cardiovascular events.
  • How is Pelacarsen administered? Pelacarsen is typically administered as a subcutaneous injection, often at a dose of 80 mg once monthly. However, specific dosing may vary depending on the particular clinical trial and patient characteristics.
  • What are the potential benefits of Pelacarsen? Clinical trials are investigating whether Pelacarsen can effectively lower Lp(a) levels, reduce the need for lipoprotein apheresis in certain patients, slow the progression of aortic valve stenosis, and ultimately decrease the risk of cardiovascular events in patients with elevated Lp(a).
  • Are there any known side effects of Pelacarsen? As with any medication in clinical trials, researchers are closely monitoring for potential side effects. Current studies are evaluating the safety and tolerability of Pelacarsen, including any adverse events that may occur during treatment. Specific side effect profiles will become clearer as more data from trials become available.

Ongoing Clinical Trials on Pelacarsen

  • Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +14

  • Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study on Pelacarsen for Slowing Calcific Aortic Valve Stenosis in Patients

    Recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +4

  • Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

    Not recruiting

    1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +14

  • Study on Reducing Lipoprotein Apheresis with Pelacarsen in Patients with High Lipoprotein(a) and Heart Disease in Germany

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Long-Term Safety of Pelacarsen for Patients with Cardiovascular Disease Who Completed the Frontiers Apheresis Study

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany

Glossary

  • Lipoprotein(a) [Lp(a)]: A type of lipoprotein in the blood that is considered an independent risk factor for cardiovascular disease. High levels of Lp(a) are associated with an increased risk of heart disease and stroke.
  • Antisense oligonucleotide (ASO): A type of therapeutic molecule designed to interfere with the production of specific proteins by binding to their messenger RNA (mRNA).
  • Atherosclerotic Cardiovascular Disease (ASCVD): A condition where plaque builds up inside the arteries, leading to narrowing and hardening of the blood vessels, which can cause heart attacks, strokes, and other cardiovascular problems.
  • Lipoprotein apheresis: A medical procedure used to remove excess lipoproteins, including Lp(a), from the blood. It's often used in patients with very high levels of lipids that don't respond adequately to other treatments.
  • Calcific Aortic Valve Stenosis: A condition where the aortic valve in the heart becomes narrowed due to calcium buildup, which can restrict blood flow and lead to heart problems.
  • Hyperlipoproteinemia(a): A condition characterized by abnormally high levels of lipoprotein(a) in the blood, which increases the risk of cardiovascular disease.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and effect.

References

  1. https://clinicaltrials.gov/study/NCT05337878
  2. https://clinicaltrials.gov/study/NCT04993664
  3. https://clinicaltrials.gov/study/NCT05900141
  4. https://clinicaltrials.eu/trial/study-on-pelacarsen-for-slowing-calcific-aortic-valve-stenosis-in-patients/
  5. https://clinicaltrials.eu/trial/study-on-reducing-lipoprotein-apheresis-with-pelacarsen-in-patients-with-high-lipoproteina-and-heart-disease-in-germany/
  6. https://clinicaltrials.gov/study/NCT05026996